Recap: Ocular Therapeutix Q3 Earnings
Portfolio Pulse from Benzinga Insights
Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings, beating estimated earnings by 13.79% with an EPS of $-0.25 versus an estimate of $-0.29. Revenue was up $3.12 million from the same period last year. Last quarter, the company beat on EPS by $0.03, which was followed by a 10.78% drop in the share price the next day.
November 07, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocular Therapeutix reported better than expected Q3 earnings, but past performance shows a drop in share price following a beat on EPS.
Ocular Therapeutix's Q3 earnings beat estimates, which is generally a positive signal. However, the company's share price dropped 10.78% the day after it beat EPS estimates last quarter. This suggests that despite the positive earnings report, investors may react negatively, potentially due to other factors not covered in the earnings report.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100